News News

September 21, 2021 Sirnaomics, Inc. to Present at TIDES USA 2021

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

July 14, 2021 Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention

Expects to Report Initial Clinical Data in Second Half of 2021  Sirnaomics, Inc., a biopharmaceutical company engaged…

July 6, 2021 Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announces today that the…

July 1, 2021 Sirnaomics Secures $105 Million Series E Financing

Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases Sirnaomics…

June 30, 2021 Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer

Company Expects to Report Interim Clinical Data of the Phase 2 in Second Half of 2021 Sirnaomics,…

1 2 3 12